M&A may seem hot in the life sciences, but that and IPO activity is starting to cool across all sectors, according to a new report from the National Venture Capital Association. The first quarter of 2015 saw less than 20 venture-backed IPOs since the first quarter of 2013. Independent of sector, when it comes to deal size, this quarter was the slowest in M&A since the first quarter of 2013.
But the bulk of the IPOs completed were, of course, in the life sciences – 13 of the 17 exits were in the medical and biotech sectors. And
“With such a blistering pace for venture-backed exit activity in 2014, it was only a matter of time before we saw a drop activity,”said Bobby Franklin, President & CEO of National Venture Capitalists Association. “Despite the decline in venture-backed IPOs for the quarter, a lot of promising young companies made their debut on the public markets with many more waiting in the wings.”
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Here’s how they looked overall:
And here’s how M&A looked in the first quarter, when divided out by sector:
Still parsing this out as it specifically applies to the life sciences sector – stay tuned.
